BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; the University of California, San Diego; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; UC San Francisco; the Canadian Glycomics Network (GlycoNet); the University of California; and Helsinn Group, as well as a clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398. The company was founded in 2015 and is headquartered in Palo Alto, California.
IPO Year: 2019
Exchange: NASDAQ
Website: bridgebio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 10/3/2024 | Perform | Oppenheimer | |
| 9/4/2024 | $46.00 | Overweight | Piper Sandler |
| 3/21/2024 | $45.00 | Outperform | Raymond James |
| 1/31/2024 | $37.00 | Market Perform | BMO Capital Markets |
| 12/8/2023 | $58.00 | Overweight | Wells Fargo |
| 12/8/2023 | Overweight | Wells Fargo | |
| 11/7/2023 | $42.00 | Buy | Citigroup |
| 10/24/2023 | $50.00 | Overweight | Cantor Fitzgerald |
| 7/18/2023 | $24.00 → $33.00 | Buy → Hold | Jefferies |
PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in Chicago, Illinois on March 29-31, 2025. Additionally, BridgeBio was selected to share five poster presentations and two moderated posters on ATTR-CM. Flatboard Poster Presentations:Acoramidis Im
PALO ALTO, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on March 19, 2025, the compensation committee of BridgeBio's board of directors approved equity grants to 10 new employees in restricted stock units for an aggregate of 30,782 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on February 16, 2026, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject
PALO ALTO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D. has been appointed President and Chief Financial Officer (CFO) of the Company. He recently assumed the role of Principal Financial Officer and will continue to lead the Company's FP&A and accounting operations. Brian Stephenson, Ph.D. will depart from the Company for personal reasons. Dr. Stephenson's departure was not the result of a disagreement with the Company on any matters relating to the Company's operations, policies or practices. Dr. Stephenson will con
Notes Investor Feedback Supporting Deep Track's Course of Action and Sharing Concerns with Company's Capital Allocation Strategy, Poor Governance, and Lack of Shareholder Perspective in the Boardroom Highlights Dynavax's Refusal to Reach a Constructive Resolution and Calls on Board to Stop Engaging in Petty "Activism Defense 101" Tactics Questions Company's Issuance of Expensive Convertible Notes in Recent Refinancing Instead of Using Cash on Hand Sets Record Straight Regarding Dynavax's Misleading Assertion That Deep Track is Seeking Control of the Board – Which is Simply False Reiterates Need for a Refreshed Board to Drive Critical Strategic Improvements and Protect the Long-Term Inte
Total proceeds, assuming no redemptions, are expected to be $450 million, combining funds held in the Helix Acquisition Corp. II trust account and a private investment in public equity (PIPE) financing Leading institutional investors commit approximately $260 million through a PIPE led by Cormorant Asset Management Business combination is expected to be completed in the third quarter of 2025 The combined entity will be named BridgeBio Oncology Therapeutics (BBOT) and will be advancing a next-generation pipeline of therapies for patients with RAS and PI3Kα malignancies TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT"), a clinical-stage biopharmaceutical company advanci
Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturityOffering priced at 1.75% interest rate and 45% conversion premium PALO ALTO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) (the "Company," "we" or "BridgeBio") announced today the pricing of $500 million aggregate principal amount of 1.75% convertible senior notes due 2031 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). In connection with the offering, the Company granted the initial purcha
- Long term debt management strategy will strengthen the balance sheet without increasing total liabilities - Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturity PALO ALTO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) (the "Company," "we" or "BridgeBio") announced today that it intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of convertible senior notes due 2031 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amende
- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR stabilizer (≥90%) was approved by the FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients on November 22, 2024 - Acoramidis was approved as BEYONTTRA™ in the EU on February 10, 2025, achieving a $75 million milestone payment and ongoing royalties in a tiered structure beginning in the low-thirties percent on sales in the EU - Acoramidis demonstrated a 59% hazard reduction on the composite endpoint of all-cause mortality and first
PALO ALTO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024, on February 20, 2025. As part of the announcement, the Company will also share updates on Attruby's commercialization progress and its late-stage clinical pipeline. The Company will begin hosting earnings calls with the Q1 earnings release, expected in late April or early May, as outlined in its JPM presentation. About BridgeBio Pharma, Inc.BridgeBio Pharma, Inc. (BridgeBio) is a new ty
The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placeboA 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30 Acoramidis is the first and only approved ATTR-CM treatment in the U.S. and EU with a label specifying near-complete stabilization(≥90%)Relative increases in serum TTR concentration
Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
3 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
8-K - BridgeBio Pharma, Inc. (0001743881) (Filer)
SCHEDULE 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
8-K - BridgeBio Pharma, Inc. (0001743881) (Filer)
144 - BridgeBio Pharma, Inc. (0001743881) (Subject)
10-K - BridgeBio Pharma, Inc. (0001743881) (Filer)
8-K - BridgeBio Pharma, Inc. (0001743881) (Filer)
144 - BridgeBio Pharma, Inc. (0001743881) (Subject)
SCHEDULE 13G/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SCHEDULE 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
144 - BridgeBio Pharma, Inc. (0001743881) (Subject)
Scotiabank initiated coverage of BridgeBio Pharma with a rating of Sector Outperform
Oppenheimer initiated coverage of BridgeBio Pharma with a rating of Perform
Piper Sandler initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $46.00
Raymond James resumed coverage of BridgeBio Pharma with a rating of Outperform and set a new price target of $45.00
BMO Capital Markets initiated coverage of BridgeBio Pharma with a rating of Market Perform and set a new price target of $37.00
Wells Fargo initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $58.00
Wells Fargo initiated coverage of BridgeBio Pharma with a rating of Overweight
Citigroup initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $42.00
Cantor Fitzgerald initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $50.00
Jefferies downgraded BridgeBio Pharma from Buy to Hold and set a new price target of $33.00 from $24.00 previously
SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SC 13G/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SC 13G/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SC 13G/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SC 13G/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SC 13G/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating Officer (COO) of the company. Dr. Trimarchi will assume his new responsibilities effective immediately and will continue to report directly to CEO and founder, Neil Kumar, Ph.D. In this newly created position, Dr. Trimarchi will be responsible for driving operational excellence, strategic planning, and overall business success at BridgeBio. He will lead cross-functional activities to develop a centralized ope
The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capital, and Longwood FundThis capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it progresses multiple assets into the clinic to treat patients with a wide variety of RAS and PI3Kα pathway malignancies PALO ALTO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commerci
PALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: Hannah Valantine, M.D., a national leader in organ transplant genomics who led the National Institutes of Health's efforts to promote diversity, equity, and inclusion in biomedical research. Dr. Valantine currently serves as a professor of medicine at Stanford University School of Medicine, where she has been a faculty member since 1987. Dr. Valantine was elected to the National Academy of Medicine in 2020 for her research in organ transplantation
PALO ALTO, Calif., Aug. 18, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that it has added three new independent directors to its board: Fred Hassan, a pharmaceutical and financial industry giant who is the former CEO of Schering-Plough and former chairman of Bausch & Lomb; Andrea Ellis, a consumer technology innovator and the chief financial officer of Lime; and Douglas Dachille, an investment management veteran and the former chief investment officer of American International
REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, announced the appointment of Franco Valle as Chief Financial Officer. Mr. Valle is an accomplished financial expert who brings extensive experiences to Biomea, in particular with building the necessary infrastructure to support clinical and operational growth within biotech companies. Mr. Valle will also assume the role of Principal Financial Officer and Principal Accounting Officer upon joining. Recently, Mr. Valle se
PALO ALTO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on January 4, 2021, the compensation committee of BridgeBio’s board of directors granted six new employees restricted stock units for an aggregate of 4,126 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the te
PALO ALTO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) recommends that BridgeBio stockholders and Eidos Therapeutics, Inc. (Nasdaq: EIDX) stockholders vote “FOR” BridgeBio’s proposed merger with Eidos and each of the other proposals to be considered at both companies’ virtual special meetings to be held on January 19, 2021. Under the proposed merger agreement, BridgeBio has agreed to acquire all of the outstanding common stock of Eidos it does not already own, representing approximately 36.3% of Eidos’ outstanding shares. Eidos stockholders will have the right t
- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR stabilizer (≥90%) was approved by the FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients on November 22, 2024 - Acoramidis was approved as BEYONTTRA™ in the EU on February 10, 2025, achieving a $75 million milestone payment and ongoing royalties in a tiered structure beginning in the low-thirties percent on sales in the EU - Acoramidis demonstrated a 59% hazard reduction on the composite endpoint of all-cause mortality and first
PALO ALTO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024, on February 20, 2025. As part of the announcement, the Company will also share updates on Attruby's commercialization progress and its late-stage clinical pipeline. The Company will begin hosting earnings calls with the Q1 earnings release, expected in late April or early May, as outlined in its JPM presentation. About BridgeBio Pharma, Inc.BridgeBio Pharma, Inc. (BridgeBio) is a new ty
- In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), oral treatment with infigratinib resulted in a statistically significant and sustained increase in annualized height velocity (AHV), with a mean change from baseline of +2.51cm/yr at Month 12, and +2.50 cm/yr at Month 18 (p=0.0015) - At Month 18, there was a statistically significant improvement in body proportionality (p-value of 0.001). The mean upper to lower body segment ratio was 1.88 at Month 18, as compared to 2.02 at baseline - Infigratinib continues to be well-tolerated as a single daily oral therapy with no adverse events (AEs) assessed as treatment-related in any participant in Cohort 5 - PROPEL 3, the global Phase 3 registrational s
- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortality (CVM), and cardiovascular-related hospitalization (CVH) in ATTR-CM participants through month 30 - Acoramidis treatment resulted in a significant improvement in the composite endpoint of CVM and CVH in ATTR-CM participants, with benefit evident as early as Month 3 - In ATTRibute-CM, participants with at least one CVH had a significantly higher risk of mortality, highlighting the need for ATTR-CM treatments that reduce risk of CVH - BridgeBio also shared the rationale and design of ACT-EAR
- BridgeBio to host investor call on Wednesday, May 29, 2024 at 5:30 pm ET, with presentations from Mathew Maurer, M.D. of Columbia University Irving Medical Center, U.S. and Ahmad Masri, M.D., M.S. of Oregon Health & Science University, U.S. PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that 12 oral and moderated poster presentations will be shared at the 2024 International Symposium on Amyloidosis (ISA), taking place in Rochester, Minnesota on May 26 - 30, 2024. BridgeBio will also host an investor call on May 2
- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related hospitalization) was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001) - The placebo and acoramidis time-to-first event Kaplan-Meier (K-M) curves for a composite of all-cause mortality (ACM) and cardiovascular-related hospitalization (CVH) separated beginning at Month 3, representing the most rapid & sustained clinical benefit on the composite endpoint of ACM and CVH in ATTR-CM patients through Month 30 (Hazard Ratio = 0.645) to the Company's knowledge - Acoramidis was well-tolerated, with no safety signals of
PALO ALTO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that additional Phase 3 data on clinical outcomes from ATTRibute-CM, its study of acoramidis in ATTR-CM will be presented at the AHA Scientific Sessions 2023, taking place in Philadelphia, Pennsylvania on November 11 - 13, 2023. As previously announced, a highly statistically significant result was observed on the primary endpoint of ATTRibute-CM with a Win Ratio of 1.8 (p<0.0001). ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigatio
- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consistently favored acoramidis treatment across key subgroups, including across both variant and wild-type ATTR patients as well as across New York Heart Association (NYHA) Class I, II, and III patients. In particular, in contrast to results observed in prior studies of TTR stabilizers, consistency against cardiovascular-related hospitalizations (CVH) was observed across all prespecified subgroups at 30 months - Absolute values observed across all-cause mortality (ACM), cardiovascular mortality (CVM) and CVH showed that over 30 months, patients survived
PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that detailed Phase 3 results from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress 2023, taking place in Amsterdam, Netherlands on August 25 - 28, 2023. ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally-administered, highly potent, small molecule stabilizer of transthyretin (TTR). BridgeBio
- Highly statistically significant result observed on primary endpoint with a Win Ratio of 1.8 (p<0.0001) - 58% of ties in Finkelstein-Schoenfeld (F-S) primary analysis broken by all-cause mortality and frequency of cardiovascular-related hospitalization; statistical significance also achieved on an F-S test with those two parameters alone (p=0.0182) - Clinically meaningful and consistent separation observed on all measures of mortality, morbidity, function, and quality of life - On-treatment survival rate of 81% versus placebo survival rate of 74% (absolute risk reduction of 6.43%; relative risk reduction of 25%) - Highly statistically significant relative risk reduction of 50